MEI Pharma, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own0.49% Shs Outstand133.06M Perf Week-6.90%
Market Cap65.45M Forward P/E- EPS next Y-0.76 Insider Trans0.00% Shs Float132.50M Perf Month-8.12%
Income-34.80M PEG- EPS next Q-0.19 Inst Own38.10% Short Float3.84% Perf Quarter-23.57%
Sales48.70M P/S1.34 EPS this Y29.10% Inst Trans-14.93% Short Ratio2.08 Perf Half Y-75.72%
Book/sh0.51 P/B0.95 EPS next Y-49.00% ROA-18.50% Target Price5.17 Perf Year-83.23%
Cash/sh1.25 P/C0.39 EPS next 5Y-0.10% ROE-62.00% 52W Range0.41 - 3.55 Perf YTD-81.91%
Dividend- P/FCF- EPS past 5Y9.50% ROI-122.10% 52W High-85.60% Beta0.81
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low26.20% ATR0.04
Employees76 Current Ratio7.70 Sales Q/Q304.20% Oper. Margin- RSI (14)47.10 Volatility6.66% 7.19%
OptionableYes Debt/Eq0.00 EPS Q/Q76.40% Profit Margin-71.60% Rel Volume1.54 Prev Close0.48
ShortableYes LT Debt/Eq0.00 EarningsSep 08 AMC Payout- Avg Volume2.45M Price0.51
Recom2.30 SMA20-3.47% SMA50-5.59% SMA200-60.16% Volume811,324 Change5.80%
Mar-25-22Downgrade Wells Fargo Overweight → Equal Weight $13 → $2
Mar-25-22Downgrade Stifel Buy → Hold $6 → $2
Mar-25-22Downgrade Jefferies Buy → Hold $4 → $1
Feb-03-22Initiated Jefferies Buy $4
Sep-22-20Initiated Alliance Global Partners Buy $9
May-29-20Initiated SunTrust Buy $16
Dec-20-18Initiated H.C. Wainwright Buy $10
Dec-20-18Initiated H.C. Wainwright Buy
Jul-27-18Upgrade Stifel Hold → Buy $2.50 → $7
Jul-13-18Initiated SunTrust Buy $12
Apr-18-16Reiterated Wedbush Neutral $3 → $2
Mar-23-15Downgrade ROTH Capital Buy → Neutral $14 → $2.50
Dec-18-14Reiterated ROTH Capital Buy $22 → $14
Oct-16-14Reiterated ROTH Capital Buy $20 → $22
Jul-08-14Resumed Brean Capital Buy $16
Oct-22-13Reiterated Stifel Buy $11 → $15
Apr-15-13Initiated Stifel Buy $11
Sep-06-22 08:00AM  
Sep-01-22 04:00PM  
Aug-18-22 10:35AM  
Aug-01-22 04:00PM  
Jul-18-22 08:00AM  
Jul-01-22 04:00PM  
Jun-22-22 08:00AM  
Jun-10-22 03:00AM  
Jun-04-22 04:00PM  
Jun-01-22 04:00PM  
May-26-22 05:00PM  
May-23-22 05:35PM  
May-17-22 08:00AM  
May-12-22 02:21PM  
May-04-22 09:15AM  
May-02-22 04:00PM  
Apr-08-22 01:00PM  
Apr-01-22 04:01PM  
Mar-28-22 05:41PM  
Mar-25-22 02:47PM  
Mar-24-22 04:01PM  
Mar-08-22 04:30PM  
Mar-01-22 04:01PM  
Feb-12-22 07:07AM  
Feb-10-22 07:25PM  
Feb-07-22 08:00AM  
Feb-01-22 04:01PM  
Jan-27-22 03:01PM  
Jan-15-22 08:50AM  
Jan-03-22 04:01PM  
Dec-06-21 04:00PM  
Dec-03-21 04:00PM  
Dec-01-21 08:46PM  
Nov-30-21 04:00PM  
Nov-29-21 04:00PM  
Nov-23-21 08:00AM  
Nov-10-21 06:35PM  
Nov-04-21 09:00AM  
Nov-02-21 03:02PM  
Nov-01-21 04:01PM  
Oct-22-21 10:46AM  
Oct-06-21 11:21AM  
Oct-01-21 04:00PM  
Sep-22-21 08:00AM  
Sep-07-21 09:03AM  
Sep-03-21 04:05PM  
Sep-02-21 05:45PM  
Aug-26-21 08:00AM  
Aug-18-21 10:36AM  
Aug-17-21 08:00AM  
Aug-05-21 04:01PM  
Aug-02-21 04:01PM  
Jul-29-21 05:54PM  
Jul-16-21 05:10AM  
Jul-07-21 08:00AM  
Jul-01-21 04:01PM  
Jun-09-21 06:00AM  
Jun-07-21 08:00AM  
Jun-04-21 08:00AM  
May-19-21 05:00PM  
May-12-21 10:00AM  
May-06-21 06:55PM  
Apr-30-21 09:00AM  
Apr-29-21 05:06PM  
Apr-13-21 07:00AM  
Apr-12-21 12:53PM  
Apr-10-21 08:30AM  
Apr-05-21 08:00AM  
Mar-12-21 10:50PM  
Mar-10-21 04:30PM  
Mar-02-21 08:00AM  
Feb-11-21 12:02AM  
Feb-05-21 10:50PM  
Feb-04-21 05:35PM  
Jan-28-21 12:32PM  
Jan-14-21 02:45AM  
Jan-04-21 07:00AM  
Dec-18-20 10:50PM  
Dec-15-20 08:40PM  
Nov-15-20 09:20AM  
Nov-10-20 04:05PM  
Nov-09-20 08:00AM  
Oct-30-20 11:03AM  
Oct-23-20 06:22PM  
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.